General Information |
| Clinical trials phase |
Phase 2 |
| Start date (estimated) |
2023-12-01 |
| End date (estimated) |
2024-11-30 |
| Clinical feature |
| Label |
Graft versus host disease |
| Link |
http://www.orpha.net/ORDO/Orphanet_39812 |
| Description |
A rare immune disease characterized by donor-derived immune cells, primarily T cells, recognizing the recipient's tissues as foreign and mounting an immune response against them. It is a significant complication following allogeneic hematopoietic cell transplantation (alloHCT). Graft versus host disease (GVHD) is classified into acute (aGVHD) and chronic (cGVHD) forms. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2300077942 |
| Other study identifiers |
| Name |
ChiCTR2300077942 |
| Description |
Chinese Clinical Trial Registry (ChiCTR) |
|
| Source weblink |
https://www.chictr.org.cn/showproj.html?proj=201633 |
| Sponsors |
West China Hospital of Sichuan University
|
Cells |
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
18 |
